vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
08 nov. 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
02 nov. 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
01 nov. 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
11 août 2023 16h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
16 juin 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
24 mai 2023 09h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
11 mai 2023 16h15 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
06 mars 2023 17h56 HE
|
vTv Therapeutics Inc.
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetesBiotech industry and Wall Street veteran Steven Tuch appointed...
Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
01 févr. 2023 17h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
13 déc. 2022 08h15 HE
|
vTv Therapeutics Inc.
Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the...